Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome - Scorecard - MDSpire
Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome
Clinical Scorecard: Assessment of Safety and Efficacy of Varying Durations of Dual Antiplatelet Therapy with Aspirin and Ticagrelor Following Successful Percutaneous Coronary Intervention in Diabetic Patients with Acute Coronary Syndrome
At a Glance
Category
Detail
Condition
Acute Coronary Syndrome in Diabetic Patients
Key Mechanisms
Dual antiplatelet therapy (DAPT) reduces stent thrombosis risk but increases bleeding risk proportional to treatment duration.
Target Population
Diabetic patients with Acute Coronary Syndrome undergoing PCI
Care Setting
Interventional cardiology, outpatient follow-up
Key Highlights
DAPT reduces major adverse cardiovascular events (MACE) but increases bleeding risk.
Study compares 3 months of DAPT followed by ticagrelor monotherapy versus 12 months of DAPT.
400 diabetic patients were randomized for the study.
Guideline-Based Recommendations
Diagnosis
Assessment of cardiovascular risk factors and symptoms in diabetic patients.
Management
Initiate DAPT with aspirin and ticagrelor post-PCI for 3 months, then consider monotherapy.
Monitoring & Follow-up
Regular follow-up for bleeding events and MACE every 3 months.
Risks
Increased bleeding risk associated with prolonged DAPT.
Patient & Prescribing Data
Diabetic patients aged 18-80 with ACS undergoing PCI.
Ticagrelor monotherapy may be considered after 3 months of DAPT to reduce bleeding risk.
Clinical Best Practices
Conduct thorough risk assessment for bleeding before initiating DAPT.
Ensure regular monitoring of patients for MACE and bleeding events.
Creatine's ATP-buffering trick isn't just for biceps. In mice, it juices up dendritic cells' energy supply, sharpening T-cell priming and shrinking tumors on daily injections. Human DCs got the memo too, at least in a dish. Early days, but a fun plot twist for gym-bag chemistry.
A consensus statement called for immediate adoption of enhanced radiation protection devices, although evidence of long-term health benefits and effectiveness across procedural settings remains limited.
Moderate coffee consumption generally appeared safe for most adults, but randomized evidence suggested divergent effects on atrial fibrillation and premature ventricular contractions.
